AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Allarity Therapeutics Statistics
Share Statistics
Allarity Therapeutics has 4.43M shares outstanding. The number of shares has increased by -28.25% in one year.
Shares Outstanding | 4.43M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 213.85% |
Owned by Institutions (%) | n/a |
Shares Floating | 3.96M |
Failed to Deliver (FTD) Shares | 5.18K |
FTD / Avg. Volume | 0.46% |
Short Selling Information
The latest short interest is 179.44K, so 4.05% of the outstanding shares have been sold short.
Short Interest | 179.44K |
Short % of Shares Out | 4.05% |
Short % of Float | 4.53% |
Short Ratio (days to cover) | 0.3 |
Valuation Ratios
The PE ratio is -55311.38 and the forward PE ratio is -0.03.
PE Ratio | -55311.38 |
Forward PE | -0.03 |
PS Ratio | 0 |
Forward PS | 0 |
PB Ratio | -239280.53 |
P/FCF Ratio | -51648.55 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Allarity Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.14, with a Debt / Equity ratio of -0.47.
Current Ratio | 0.14 |
Quick Ratio | 0.14 |
Debt / Equity | -0.47 |
Total Debt / Capitalization | -89.59 |
Cash Flow / Debt | -9.8 |
Interest Coverage | -36 |
Financial Efficiency
Return on equity (ROE) is 4.33% and return on capital (ROIC) is 1165.42%.
Return on Equity (ROE) | 4.33% |
Return on Assets (ROA) | -1% |
Return on Capital (ROIC) | 1165.42% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.38M |
Employee Count | 5 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | -717.00K |
Effective Tax Rate | 0.06 |
Stock Price Statistics
The stock price has increased by -99.65% in the last 52 weeks. The beta is 0.29, so Allarity Therapeutics 's price volatility has been higher than the market average.
Beta | 0.29 |
52-Week Price Change | -99.65% |
50-Day Moving Average | 1.17 |
200-Day Moving Average | 15.23 |
Relative Strength Index (RSI) | 42.92 |
Average Volume (20 Days) | 1.13M |
Income Statement
Revenue | n/a |
Gross Profit | -37.00K |
Operating Income | -17.93M |
Net Income | -11.90M |
EBITDA | -12.08M |
EBIT | n/a |
Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 166.00K in cash and 1.30M in debt, giving a net cash position of -1.13M.
Cash & Cash Equivalents | 166.00K |
Total Debt | 1.30M |
Net Cash | -1.13M |
Retained Earnings | -94.45M |
Total Assets | 20.38M |
Working Capital | 12.95M |
Cash Flow
In the last 12 months, operating cash flow was -12.74M and capital expenditures 0, giving a free cash flow of -12.74M.
Operating Cash Flow | -12.74M |
Capital Expenditures | 0 |
Free Cash Flow | -12.74M |
FCF Per Share | -0.01 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ALLR does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -0.99% |
FCF Yield | -284.62% |
Analyst Forecast
Currently there are no analyst rating for ALLR.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 11, 2024. It was a backward split with a ratio of 1:30.
Last Split Date | Sep 11, 2024 |
Split Type | backward |
Split Ratio | 1:30 |
Scores
Altman Z-Score | -9.55 |
Piotroski F-Score | 4 |